Author | Arthur L. Burnett, II, MD, MBA


Oral testosterone agents mark important paradigm shift

June 12, 2020


"The rigorous study and promising clinical availability of oral therapy for testosterone deficiency are flash points in the current era, in which the utility of testosterone therapy is under critical review," writes Arthur L. Burnett II, MD, MBA.

Pandemic brings new challenges, opportunities-and resilience

April 15, 2020


"For many of us, we will repurpose in new enterprises, new business models, and new opportunities for work productivity and life utility. We will be resilient," writes Arthur L. Burnett, II, MD, MBA.

Post-prosthesis infection data alter conventional thinking

March 29, 2019


"The observations that penile prosthesis surgical infections occurring early are frequently associated with anaerobic bacterial organisms and that these infections overall comprise diverse pathogens including fungal organisms fundamentally alter conventional thinking related to this topic area," writes Arthur L. Burnett, II, MD, MBA.

New AUA ED guideline reflects paradigm change

May 31, 2018


Arthur L. Burnett, II, MD, MBA, discusses some of the significant differences between the 2018 and 2005 AUA guidelines on ED as well as how the new guideline addresses novel treatments that are not currently FDA approved.